Skip to main content
assistive.skiplink.to.breadcrumbs
assistive.skiplink.to.header.menu
assistive.skiplink.to.action.menu
assistive.skiplink.to.quick.search

Pages

Recently Updated

4. Metastatic, castration-resistant
Jan 06, 2014 • updated by Nancy Dawson • view change
3. Metastatic, hormone-sensitive
Oct 23, 2013 • updated by Nancy Dawson • view change
HUH - Phase I and II Study of Safety and Efficacy of Muscadine Plus, MPX, in Men with Prostate Cancer- A Randomized Dose-Finding Study of 2 Doses of MPX on Rising PSA following Initial Therapy
Sep 18, 2013 • updated by Nancy Dawson • view change
2. Biochemical recurrence
Sep 18, 2013 • updated by Nancy Dawson • view change
HUH - Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Sep 18, 2013 • updated by Nancy Dawson • view change
5. Non-therapeutic
Sep 18, 2013 • updated by Nancy Dawson • view change
HUH - A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Sep 18, 2013 • updated by Nancy Dawson • view change
AOH - EVEREST - EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Sep 18, 2013 • updated by Nancy Dawson • view change
1. General
Sep 18, 2013 • updated by Nancy Dawson • view change
GUH - A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Sep 16, 2013 • updated by Nancy Dawson • view change
JHMI J1287 A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Sep 16, 2013 • updated by Nancy Dawson • view change
2. Metastatic
Sep 16, 2013 • updated by Nancy Dawson • view change
JHMI J1249 A Phase Ib/II Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Sep 16, 2013 • updated by Nancy Dawson • view change
1. Localized
Sep 16, 2013 • updated by Nancy Dawson • view change
JHMI - J1346 - A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression - Hoosier Oncology Group GU12-157
Sep 16, 2013 • updated by Nancy Dawson • view change

Show More

Please wait

Tree browser

Browse and reorder all pages